Karin Larmené- Beld

Dr. Karin Larmené- Beld

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2019 in European Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
KBKarin Larmené- Beld
Karin Larmené- Beld
HFHenderik Frijlink
Henderik Frijlink
KTKatja Taxis
Katja Taxis
Preparation of parenteral medication in hospitals is a complex process with a risk of microbial contamination of the product, especially when inappropriately prepared. Contaminated parenteral medications can cause severe complications to patients and increase morbidity in hospitals. The aim of this literature review is to systematically evaluate the contamination rate of parenteral medications in hospitals prepared in a pharmacy environment and a clinical environment.

12 May 2018 in European Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
KBKarin Larmené- Beld
Karin Larmené- Beld
EAE. Kim Alting
E. Kim Alting
KTKatja Taxis
Katja Taxis
Purpose Unclear labeling has been recognized as an important cause of look-alike medication errors. The aim of this literature review is to systematically evaluate the current evidence on strategies to minimize medication errors due to look-alike labels. Methods A literature search of PubMed and EMBASE for all available years was performed independently by two reviewers. Original studies assessing strategies to minimize medication errors due to look-alike labels focusing on readability of labels by health professionals or consumers were included. Data were analyzed descriptively due to the variability of study methods. Results Sixteen studies were included. Thirteen studies were performed in a laboratory and three in a healthcare setting. Eleven studies evaluated Tall Man lettering, i.e., capitalizing parts of the drug name, two color-coding, and three studies other strategies. In six studies, lower error rates were found for the Tall Man letter strategy; one showed significantly higher error rates. Effects of Tall Man lettering on response time were more varied. A study in the hospital setting did not show an effect on the potential look-alike sound-alike error rate by introducing Tall Man lettering. Color-coding had no effect on the prevention of syringe-swaps in one study. Conclusions Studies performed in laboratory settings showed that Tall Man lettering contributed to a better readability of medication labels. Only few studies evaluated other strategies such as color-coding. More evidence, especially from real-life setting is needed to support safe labeling strategies.

1 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Herman J. WoerdenbagHerman J. Woerdenbag
Herman J. Woerdenbag
POPeter Olinga
Peter Olinga
EKEllen A. Kok
Ellen A. Kok
DBDonald Brugman
Donald Brugman
UAUlrike F. van Ark
Ulrike F. van Ark
MNMaarten W. Nijkamp
Maarten W. Nijkamp
The application of cannabis products in oncology receives interest, especially from patients. Despite the plethora of research data available, the added value in curative or palliative cancer care and the possible risks involved are insufficiently proven and therefore a matter of debate. We aim to give a recommendation on the position of cannabis products in clinical oncology by assessing recent literature. Various types of cannabis products, characteristics, quality and pharmacology are discussed. Standardisation is essential for reliable and reproducible quality. The oromucosal/sublingual route of administration is preferred over inhalation and drinking tea. Cannabinoids may inhibit efflux transporters and drug-metabolising enzymes, possibly inducing pharmacokinetic interactions with anticancer drugs being substrates for these proteins. This may enhance the cytostatic effect and/or drug-related adverse effects. Reversely, it may enable dose reduction. Similar interactions are likely with drugs used for symptom management treating pain, nausea, vomiting and anorexia. Cannabis products are usually well tolerated and may improve the quality of life of patients with cancer (although not unambiguously proven). The combination with immunotherapy seems undesirable because of the immunosuppressive action of cannabinoids. Further clinical research is warranted to scientifically support (refraining from) using cannabis products in patients with cancer.

3 July 2014 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Open access
PDF file
PHP. G. J. ter Horst
P. G. J. ter Horst
KBKarin Larmené- Beld
Karin Larmené- Beld
JBJ. Bosman
J. Bosman
EVE. L. van der Veen
E. L. van der Veen
AWAndré Wieringa
André Wieringa
JSJ. P. Smit
J. P. Smit
Depression during pregnancy is common and includes risks for mother and child. Pharmacokinetics of venlafaxine may be changed during pregnancy. This study aimed to describe changes in metabolic ratios and concentrations of venlafaxine and its main metabolite O-desmethylvenlafaxine during and after pregnancy. To study this, we used data from our study of compliance to Antidepressants During Pregnancy (the ADAP study) to investigate the course of venlafaxine and O-desmethylvenlafaxine concentrations during pregnancy and in the period post-partum. We found that the venlafaxine concentration significantly changed during pregnancy when compared to the post-partum period (P = 0·028). The median concentration of venlafaxine in the first trimester was 98·9% (54·2-292·0%), the second 100·0% (46·5-264·0%) and the third trimester 87·0% (61·5-217·2%). We did not found differences in O-desmethylvenlafaxine concentrations in the different trimesters of pregnancy compared with the post-partum period, P = 0·565. Also the ratio of O-desmethylvenlafaxine/venlafaxine concentrations increased significantly from 76·9% (range 32·8-142·0%) in the first trimester to 196·7% (range 83·3-427·6%) in the third trimester compared with the post-partum period, P = 0·004. Further, three of seven patients had concentrations below the therapeutic reference range (100-400 μg/L) in any period of pregnancy, whereas no one had subtherapeutic concentrations in the post-partum period. Venlafaxine concentrations decreases during pregnancy, and the ratio of the concentrations of O-desmethylvenlafaxine/venlafaxine increases during pregnancy. Pregnant women using venlafaxine are at risk for subtherapeutic concentrations, therefore routine monitoring of concentrations venlafaxine and O-desmethylvenlafaxine is recommendable during pregnancy.

14 January 2014 in Biomedical Chromatography
Verified
Journal Article
Closed access
PDF file
KBKarin Larmené- Beld
Karin Larmené- Beld
MVMarie‐Therese L. M. Vries‐Koenjer
Marie‐Therese L. M. Vries‐Koenjer
PHPeter G. J. ter Horst
Peter G. J. ter Horst
WHWobbe Hospes
Wobbe Hospes

8 June 2010 in Australasian Journal on Ageing
Verified
Journal Article
Closed access
PDF file
JWJuanita Westbury
Juanita Westbury
KBKarin Larmené- Beld
Karin Larmené- Beld
SJShane Jackson
Shane Jackson
Gregory PetersonGregory Peterson
Gregory Peterson